BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.
Nils Eckardt, Vice President Medical Affairs, Europe, shares BeiGene’s innovative vision for patients.
A short summary describing an antibody targeting TIM-3 which enhances T cell activity and NK-cell tumor cytotoxicity and may help overcome anti-PD-1 resistance in solid tumors.

Chat with BeiGene